Ocuphire Pharma Investor Day Presentation Deck

P 97 Two Treatment Options for Spectrum of Presbyopic Patients Two NDA Submissions Targeted in 2023: Nyxol Alone and Nyxol+LDP Pursuing Product Labels for 1 Drop and 2 Drop Options for the Treatment of Presbyopia Nyxol as a Single Agent for Presbyopia Single Durable Drop F Nyxol with LDP as Adjunctive Therapy for Presbyopia Two Drops Tunable Option Initiating VEGA Phase 3 Program in Mid-2022 for Both Labels Ocuphire PHARMA

View entire presentation